Duchenne muscular dystrophy

New treatments = HUGE COSTS

Up to $900,000 per member with Duchenne muscular dystrophy (DMD), per year.

DMD is caused by a gene mutation. It’s the most common and most severe form of muscular dystrophy.

Symptoms:
• Muscular weakness and fatigability
• Muscle pain and cramps

30+ forms of muscular dystrophy

30% of patients with DMD

Glucocorticoids (such as prednisone) are the only existing treatments

New treatments are arriving

Some clinical studies show potential for slowing disease progression and improving symptoms, but impact in a real-world patient population is unknown.

Exondys 51™ (eteplirsen)


Eteplirsen for the treatment of Duchenne muscular dystrophy.

First-ever approved gene-modifying treatment

13% of patients with DMD

Eteplirsen improves muscle strength and function in 51 Duchenne muscular dystrophy (DMD) patients.

Enzyme replacement:

deflazacort


New research suggests potential side-effect improvement in reducing bone density.

The impact

Increase under the medical benefit

$2.74 to $4.57

Through patient-centered care and smart drug cost management, Prime Therapeutics (Prime) helps the right people get the right medicine, at the right price.

For the latest information on drugs, trends and the pharmacy benefit management industry, visit Prime’s newsroom at PrimeTherapeutics.com

Drug pipeline profile

- 50% of all muscular dystrophy cases are DMD
- Up to $500,000 TO $1,000,000 per patient per year

Pricing information over existing treatments

$300,000–$500,000

Dosing based on weight

Intravenous infusion therapy

Duchenne muscular dystrophy cases are DMD = 50 percent of all muscular dystrophy cases

13% of which have exon 51 amenable deletions and may qualify for eteplirsen.